Mckinley Capital Management LLC Delaware acquired a new position in shares of Emergent Biosolutions Inc (NYSE:EBS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 84,640 shares of the biopharmaceutical company’s stock, valued at approximately $4,089,000. Mckinley Capital Management LLC Delaware owned approximately 0.16% of Emergent Biosolutions as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Pearl River Capital LLC purchased a new stake in Emergent Biosolutions in the first quarter valued at $34,000. Quantamental Technologies LLC grew its stake in shares of Emergent Biosolutions by 101.4% in the first quarter. Quantamental Technologies LLC now owns 999 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 503 shares in the last quarter. Clarus Wealth Advisors grew its stake in shares of Emergent Biosolutions by 30.7% in the second quarter. Clarus Wealth Advisors now owns 2,114 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 496 shares in the last quarter. KBC Group NV acquired a new stake in shares of Emergent Biosolutions in the second quarter valued at $126,000. Finally, Smithfield Trust Co. grew its stake in shares of Emergent Biosolutions by 15.0% in the first quarter. Smithfield Trust Co. now owns 2,812 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 366 shares in the last quarter. Hedge funds and other institutional investors own 87.48% of the company’s stock.

In related news, Director Kathryn C. Zoon sold 1,376 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $43.39, for a total transaction of $59,704.64. Following the completion of the transaction, the director now directly owns 24,379 shares of the company’s stock, valued at approximately $1,057,804.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 14.10% of the company’s stock.

A number of equities research analysts have recently weighed in on EBS shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Emergent Biosolutions in a research note on Thursday, May 2nd. ValuEngine cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. Wells Fargo & Co dropped their price objective on Emergent Biosolutions to $61.00 and set a “market perform” rating for the company in a research note on Friday, May 10th. Finally, Cowen reaffirmed a “hold” rating and issued a $60.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $70.33.

Shares of NYSE EBS traded down $0.78 during trading on Friday, reaching $40.82. The stock had a trading volume of 274,474 shares, compared to its average volume of 333,329. Emergent Biosolutions Inc has a fifty-two week low of $39.64 and a fifty-two week high of $73.89. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.53 and a current ratio of 2.30. The business’s 50-day moving average price is $43.76 and its 200-day moving average price is $49.53. The company has a market cap of $2.15 billion, a P/E ratio of 17.52, a PEG ratio of 0.68 and a beta of 1.60.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). Emergent Biosolutions had a positive return on equity of 6.68% and a negative net margin of 2.04%. The company had revenue of $243.20 million for the quarter, compared to analyst estimates of $217.94 million. During the same period in the previous year, the firm earned $1.07 earnings per share. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Analysts forecast that Emergent Biosolutions Inc will post 3.05 EPS for the current fiscal year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

See Also: What are defining characteristics of a correction?

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.